日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and Efficacy of ICP-332 for Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized Clinical Trial

ICP-332治疗中重度特应性皮炎的安全性和有效性:一项II期随机临床试验

Xu, Jinhua; Zhang, Litao; Liang, Yunsheng; Ji, Chao; Xu, Ai'e; Li, Zhiming; Li, Linfeng; Lei, Tiechi; Zhang, Chunlei; Chen, Rixin; Tao, Xiaohua; Zhang, Ruzhi; Fang, Hong; Zheng, Jie; Yang, Wenlin; Zhang, Guoqiang; Duan, Xinsuo; Ding, Yangfeng; Yin, Wenhao; Zhou, Wei; Fan, Danbing; Du, Yue

Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study

SYN008 与奥马珠单抗治疗难治性慢性自发性荨麻疹患者的等效性:一项多中心、随机、双盲、平行组、活性对照的 III 期研究

Li, Jingyi; Liang, Yunsheng; Feng, Wenli; Deng, Liehua; Fang, Hong; Ji, Chao; Lin, Youkun; Zhang, Furen; Xia, Rushan; Zhang, Chunlei; Guo, Shuping; Lin, Mao; Li, Yanling; Zhang, Shoumin; Kang, Xiaojing; Chen, Liuqing; Song, Zhiqiang; Yao, Xu; Li, Chengxin; Han, Xiuping; Guo, Guoxiang; Guo, Qing; Duan, Xinsuo; Li, Jie; Su, Juan; Li, Shanshan; Sun, Qing; Tao, Juan; Ding, Yangfeng; Deng, Danqi; Li, Fuqiu; Suo, Haiyun; Wu, Shunquan; Qiu, Jingbo; Luo, Hongmei; Li, Linfeng; Li, Ruoyu

Efficacy and Safety of 611 in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Phase II Trial

611治疗中国中重度特应性皮炎成年患者的疗效和安全性:一项II期临床试验的结果

Zhao, Yan; Zhang, Litao; Wu, Liming; Duan, Xinsuo; Ji, Chao; Xiao, Rong; Ji, Mingkai; Liu, Lunfei; Yang, Bin; Hu, Guohong; Feng, Yanyan; Zhu, Jianjian; Li, Jianguo; Ding, Yangfeng; Huang, Haomin; Zhou, Qinghong; Xu, Yuyu; Zhang, Jianzhong

Long non-coding RNA CYTOR promotes the progression of melanoma via the miR-485-5p/GPI axis.

长链非编码RNA CYTOR通过miR-485-5p/GPI轴促进黑色素瘤的进展

Lu Haitao, Zhao Yunhua, Zhang Yanli, Shi Shaomin, Hu Huanrong, Li Xuefei, Niu Yandong, Qi Haihua, Ji Shang, Duan Xinsuo, Liu Yaling

Exploring drug-induced pemphigus findings from the FDA adverse event reporting system database

探索来自FDA不良事件报告系统数据库的药物诱发性天疱疮研究结果

Niu, Yandong; Lu, Haitao; He, Lei; Wang, Zhanbo; Duan, Xinsuo

Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension

替拉珠单抗治疗中国中重度斑块状银屑病患者:一项为期 12 周的随机、安慰剂对照 III 期临床试验及长期扩展研究

Yu, Chen; Geng, Songmei; Yang, Bin; Deng, Yunhua; Li, Fuqiu; Kang, Xiaojing; Bi, Mingye; Zhang, Furen; Zhao, Yi; Pan, Weili; Tian, Zhongwei; Xu, Jinhua; Zhang, Zhenghua; Yu, Nan; Duan, Xinsuo; Guo, Shuping; Sun, Qing; Li, Weiquan; Tao, Juan; Liu, Zhijun; Yin, Yuanyuan; Wang, Gang

Metabolomic differences between exanthematous drug eruption and infectious mononucleosis

皮疹性药物疹与传染性单核细胞增多症的代谢组学差异

Liu, Yanqiu; Guan, Qizhen; Liu, Liyuan; Ma, Lina; Duan, Xinsuo; Che, Jiaozi